Undisclosed

all catalysts(0)

nothing on the calendar yet

News(10)

• MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troubles
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 2d ago
• Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
  The terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts.
  biospace · 2d ago
• Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset
  Mereo BioPharma’s asset, dubbed alvelestat, is set to enter Phase 3 development for AATD-LD in 2027.
  biospace · 3d ago
• Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
  Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.
  biopharma_dive · 4d ago
• After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
  Insilico Medicine CEO Alex Zhavoronkov’s mad dash across the BIO International Convention in June attracted plenty of eyes. But the executive would prefer industry watchers gawk at the billions of…
  biospace · 4d ago
• Epicrispr, Infinimmune snag combined $165M in VC cash
  Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.
  biospace · 4d ago
• Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
  Sentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.
  fiercebiotech · 4d ago
• AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
  News of the joint venture comes months after AstraZeneca vowed to spend $15 billion in China by the end of the decade.
  biospace · 5d ago
• Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
  Jazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.
  fiercebiotech · 5d ago
• STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
  Excluding rare disease therapies from a Medicare pilot program to lower drug prices would wipe out much of the savings from retail drugs, according to new research.
  stat · 10d ago